Incyte signed a major deal with Pfizer to develop, manufacture and market the oral chemokine receptor CCR2 antagonists. The deal could be worth up to US$803 M to Incyte if specific milestones and sales targets in all indications excluding multiple sclerosis and one other indication are met.